Recurrent Lymphoma Completed Phase 1 Trials for Temsirolimus (DB06287)

IndicationStatusPhase
DBCOND0073930 (Recurrent Lymphoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02343718Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS TumoursTreatment